Search results

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 17 July 2019

An alert was issued about Dialog+ haemodialysis machines.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 23 September 2020

Following a review of the risks associated with use of opioid medicines for non-cancer pain, the Commission on Human Medicines (CHM) has recommended that fentanyl transdermal patches are...

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 26 August 2020

A summary of letters and drug alerts recently sent to healthcare professionals, including recommendations to reduce handling errors with leuprorelin-containing depot medicines.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 31 July 2020

A summary of letters and drug alerts recently sent to healthcare professionals.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 26 August 2020

We inform healthcare professionals of the recent campaign to promote awareness of the risk and new resources available to support safe use following previous advice to health and care professionals.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 21 May 2020

A summary of letters and drug alerts recently sent to healthcare professionals.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 27 April 2020

Key MHRA advice and guidance issued so far on medicines safety and pharmacovigilance, including on reporting to the Yellow Card Scheme.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 27 April 2020

A summary of letters and drug alerts recently sent to healthcare professionals.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 21 May 2020

Guidance has been published to support initiation of valproate in female patients and for annual review and pregnancy testing during the coronavirus pandemic.

Read Summary

Type:

Safety Alerts (Remove filter)

Source:

GOV UK (Add filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 21 May 2020

Guidance has been published about thalidomide, lenalidomide, and pomalidomide and the use of remote consultations and home pregnancy testing for patients taking them during COVID-19.

Read Summary

Type:

Safety Alerts (Remove filter)